MAPLE GROVE, Minn., March 17, 2017 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced that it has entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute three generic products. These products will compete in markets with combined U.S. annual sales of nearly $200 million, according to IMS Health.
Under the terms of the agreement, the partner will develop, manufacture and supply the products exclusively for Upsher-Smith, which will market and distribute the products under its own label in the United States. Financial terms related to the deal have not been disclosed.
"We are pleased to have entered into a partnership that will help Upsher-Smith build on its already strong presence in the U.S. generic marketplace," said Rusty Field, President, Upsher-Smith. "We look forward to creating more such partnerships with companies who share in our commitment to delivering quality, high-value generic products to patients."
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.
SOURCE Upsher-Smith Laboratories, Inc.